Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503676-25-01

Acronym

POSEIDON

Enrollment

157

Registered

2024-11-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Brief summary

Rate of patients without disease progression after 4 months from the treatment start according to PCWG3

Detailed description

Progression free-survival by Kaplan-Meier method, Overall survival by Kaplan-Meier method, Biochemical response rate, Objective response rate according to RECIST criteria, Adverse events type and grade according to CTCAE v.5, Scales of FACT-P and BPI questionnaires

Interventions

DRUGDEXAMETHASONE

DRUGCHLORPHENAMINE

DRUGCarboplatino Hikma 10 mg/ml soluzione per infusione

DRUGLEUPRORELIN

DRUGTRIPTORELIN

DRUGLOPERAMIDE

DRUGDocetaxel Accord 20 mg/1 ml concentrate for solution for infusion

DRUGDEGARELIX

DRUGGOSERELIN

DRUGFILGRASTIM

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Rate of patients without disease progression after 4 months from the treatment start according to PCWG3	—

Secondary

Measure	Time frame
Progression free-survival by Kaplan-Meier method, Overall survival by Kaplan-Meier method, Biochemical response rate, Objective response rate according to RECIST criteria, Adverse events type and grade according to CTCAE v.5, Scales of FACT-P and BPI questionnaires	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026